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Proton therapy is an expanding radiotherapy modality in the United States and worldwide. With the
number of proton therapy centers treating patients increasing, so does the need for consistent, highquality clinical commissioning practices. Clinical commissioning encompasses the entire proton therapy system’s multiple components, including the treatment delivery system, the patient positioning
system, and the image-guided radiotherapy components. Also included in the commissioning process
are the x-ray computed tomography scanner calibration for proton stopping power, the radiotherapy
treatment planning system, and corresponding portions of the treatment management system. This
commissioning report focuses exclusively on intensity-modulated scanning systems, presenting
details of how to perform the commissioning of the proton therapy and ancillary systems, including
the required proton beam measurements, treatment planning system dose modeling, and the equipment needed. © 2020 American Association of Physicists in Medicine [https://doi.org/10.1002/
mp.14546]
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1. TERMINOLOGY
The development of proton therapy has resulted in extensive specialized terminology. This report follows the terminology set forth in the American Association of Physicists in
Medicine (AAPM) Summer School monograph Principles
and Practice of Proton Therapy.1 Table I lists the related terminology used in this report.

6.B.1. Mitigating range uncertainty due to immobilization devices
6.B.1. Specialized immobilization devices
6.C. High–atomic number materials in proton beams
7. COMMISSIONING IMAGE GUIDANCE SYSTEMS FOR PROTON
THERAPY
7.A. Planar image guidance
7.B. Volumetric image guidance
8. TREATMENT MANAGEMENT SYSTEM COMMISSIONING
8.A. Background
8.B. Commissioning
9. PROTON MACHINE ABSOLUTE DOSE CALIBRATION
9.A. Radiobiological effectiveness factor
9.B. Calibration protocol
9.C. Reference field and point of measurement
9.D. Ionization chamber choice and associated uncertainties
9.D.1. 60-Co ionization chamber calibration uncertainty
9.D.2. Long-term ionization chamber stability uncertainty
9.D.3. Calibration ionization chamber choice and absolute dosimetry
uncertainties
9.E. Interfacility comparisons and remote auditing
10. OUT-OF-FIELD DOSE FROM PROTON THERAPY
11. RADIOTHERAPY PLANNING SYSTEM COMMISSIONING
11.A. Dose modeling for treatment planning
11.A.1. Analytical dose model representation
11.A.2. Modeling low-dose halo
11.A.3. Accuracy and limitations of analytical dose algorithms
11.A.4. Monte Carlo as a dose model for treatment planning
11.B. Apertures and energy absorbers
11.C. Dose normalization to absolute dose
11.D. Dose model data acquisition

2. INTRODUCTION
Proton therapy is a radiotherapy modality that is being
used increasingly in the United States and worldwide. As the
number of proton therapy centers treating patients increases,
so does the need for consistent, high-quality clinical commissioning standards and procedures.
Clinical commissioning addresses multiple components of
the proton therapy system (PTS), including the treatment
delivery system (TDS), the patient positioning system (PPS),
and the image-guided radiotherapy (IGRT) components.
Also, the commissioning process includes calibration of the
x-ray computed tomography (CT) for stopping power determination. Beam modeling and verification are needed for the
treatment planning system (TPS), as well as configuration
and verification of the corresponding portions of the treatment management system (TMS), which is also sometimes
termed the oncologic information system (OIS).
If beam-modifying devices are used, their manufacture
and dosimetric characterization are also included in the commissioning process. Today’s PTSs are highly integrated;
therefore, commissioning activities should ensure the proper
operation of the various individual subsystems, as well as of
the complete integrated system. Lastly, commissioning also
includes the development of system-specific and patientspecific quality assurance (QA) procedures and user training.
System-specific QA, as well as a general description of proton therapy systems, is addressed elsewhere.2

11.D.1. Integral depth-dose measurement, scaling, and corrections
11.D.2. Spot profiles
11.D.3. Virtual source–to-axis distance

3. PURPOSE AND SCOPE OF THIS REPORT

11.D.4. Energy absorbers
11.D.5. Ripple filters
11.D.6. Apertures
11.E. Monitor unit determination
11.F. Beam model verification
11.G. Role of Monte Carlo in data modeling
12. END-TO-END VERIFICATION
12.A. Scope of end-to-end verification
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New proton therapy centers use intensity modulated proton therapy (IMPT). This report provides specific details on
how to perform the commissioning of IMPT systems. The
required proton beam measurements and the techniques and
equipment necessary to collect them are provided.
The use of scanning systems for ocular applications is a
developing application,3 as are scanned proton mini-beams,4
and both are outside the scope of this report. Also, the
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TABLE I. Proton therapy–specific terminology.
Term
(recommended)

Abbreviation/
acronym

Definition

Aperture

The non-attenuating opening in a collimator, shaped irregularly according to the
shape of the target, that allows radiation to reach a target

Beam

A group of particles or rays traveling in the same direction in parallel or
diverging from a point
The energy at the treatment head (nozzle) entrance. This is a generic term that
may also specify the beam at positions other than the treatment head, in which
case this should be stated

Beam energy

Beam energy
spread

The energy spread (sigma) at the treatment head entrance. This is a generic term
that may also specify the beam energy spread at positions other than the
treatment head, in which case this should be stated

Beamline

A device or combination of devices used to deliver a beam from an accelerator
to a specific location (e.g., a treatment room)

Beamlet

(For scanning beams and IMPT). A monoenergetic particle beam of small crosssection that enters the nozzle and reaches the patient or phantom without being
scattered or modulated. A range shifter may be inserted to reduce the range.
Another term, "pencil beam," has become common in the field of particle
therapy. For instance, "pencil-beam scanning," or PBS, is used to describe
scanning beams. Therefore, either "beamlet" or "pencil beam" may be used.
However, because the term "pencil beam" is also used to refer to a conceptual
tool in dose-calculation algorithms, its use to describe the beam of particles
entering the scanned delivery should be clearly indicated
The depth-dose curve for a beamlet beam, or the depth-dose curve of a broad
beam of quasi-monoenergetic charged particles

Bragg curve
Bragg peak
Control point

Alternate term
Collimator

Pencil beam

The narrow, high-dose region at depths near the maximum dose on a Bragg
curve near the end of proton range
CP

CP is a DICOM RT term. It refers to a delivery device that changes setting
during delivery. For instance, in pencil-beam scanning, CP specifies the
positions and weights for a collection of spots in a given energy layer

Distal fall-off
region

The distal part (beyond the Bragg peak or SOBP) of the particle depth-dose
curve

Distal penumbra

The distance between the depth of a specific percentage of the dose at the Bragg
peak (or SOBP) and the depth of a lower percentage of the Bragg peak (or
SOBP) dose in the distal fall-off region. Typically, the distal penumbra is
defined as the distance between the 80% and 20% dose values

Energy absorber

A block of low atomic number material of uniform thickness inserted in a beam
for the purpose of reducing the energy (and range) of the beam. In some cases,
an energy absorber is placed near the patient to preserve penumbral sharpness

Pre-absorber, range shifter

The product of the physical dose in Gy and the RBE used as the unit of dose

Cobalt Gray equivalent (CGE); is an
alternative, similar quantity that is
superseded by Gy (RBE)

The low-level secondary particle radiation field extending outside the lateral and
distal penumbrae of a primary beam. The halo may contain components from
the machine and the patient

Nuclear halo

Gy (RBE)

Gy (RBE)

Halo

Integral depth
dose

IDD

The integral of the dose on an infinite plane normal to the central axis of a
beam, beamlet or an infinitesimal pencil beam. It is represented as a function of
depth

Intensitymodulated
proton therapy

IMPT

One of the multiple modes of proton therapy planning and delivery methods in
which scanned beamlets of a sequence of energies and of optimized intensities
are used to achieve an appropriate balance between the target dose and the
normal tissue doses

Lateral
penumbra

LPxx-yy
(e.g., LP8020)

The distance between the point at which the dose is a certain percentage of the
central axis value and the point at which the dose is a lower percentage of the
central axis value. Typically, the penumbra is defined as the distance between
the 80% and 20% dose values

LSP

The energy lost by a charged particle in traversing a unit distance in the medium

Layer
Linear stopping
power

The irradiation with a scanned monoenergetic beam of protons

Medical Physics, 48 (1), January 2021
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TABLE I. Continued.
Term
(recommended)

Abbreviation/
acronym

Matched
treatment rooms

Twinned
treatment
rooms

Modulation
width

Definition
Treatment rooms that are dosimetrically and physically equivalent within
acceptable tolerances
The distal dose fall-off position minus the proximal dose fall-off position in a
SOBP in water. The position has to be explicitly stated, for example, "98−90,"
reflecting a 98% proximal dose fall-off position minus a 90% distal dose fall-off
position

Multiple
Coulomb
scattering

MCS

The primary scattering process of protons, which is due to electrostatic
interactions with nuclei. Multiple small-angle deflections of charged particles
traversing a medium due to Coulomb scattering from nuclei result in the lateral
spreading of proton beams

Multi-layer
ionization
chamber

MLIC

A device similar to a Multi-Layer Faraday Cup (MLFC) but consisting of
multiple layers of parallel plate ionization chambers, providing a fixed WET
separation. As with an MLFC, an MLIC allows rapid range measurement before
beam delivery to the patient. It is also used for off-line quality assurance
purposes

Nozzle

Patient
positioning
system
Pencil beam

The part of a beam delivery system in the treatment room (attached to the gantry
in rooms with gantries) into which the narrow beam of protons enters, which
houses the beam-shaping and dose-monitoring equipment and from which the
radiation emerges
PPS

The relatively uniform region of a depth-dose distribution between the surface
and the SOBP of a range-modulated beam or between the surface and the peak
of a non–range-modulated (pristine monoenergetic) beam
A monoenergetic, unscattered beam of particles. It may be a single beamlet or a
beam composed of uniformly scanned beamlets of the same energy. The term
may also be used for beams that have a narrow and symmetric energy spread

Pristine beam

Nonlinear
Response
Saturation
Range

The physical device that supports the patient and moves them into the treatment
position. It usually has 6 degrees of freedom of motion
A mathematical construct comprising a monoenergetic beam of particles with
an infinitesimal lateral dimension and angular emittance at the point of
consideration (e.g., at the point of incidence on the patient). The pencil beam
construct used in an algorithm to calculate dose distributions for large fields.
(Note the distinction between a pencil beam and a beamlet. Many authors use
the term "pencil beam" to mean a beamlet, that is, a beam of small crosssection. The pencil beam may be called the "infinitesimal" or "calculational"
pencil beam. To avoid confusion, the intended meaning of "pencil beam" should
be clearly stated.)

Plateau

In ionizing radiation detection, the phenomenon that can occur when the
detector/sensor no longer responds in proportion to absorbed dose, for example,
recombination in an ionization chamber and quenching in a scintillator
Rxx (e.g.,
R80 or R90)

Alternate term

The mean penetration depth of a charged particle beam. In this report, we define
range as the depth at which the absorbed dose of a beam falls off to a fraction of
the maximum value just beyond the Bragg Peak. Range increases with beam
energy and decreases with the mass density and linear stopping power of the
absorber. Consequently, it is convenient to specify range values in liquid water
at unit density. For comparison with traditional range tables from the literature,
R80 is used. For clinical purposes, R90 is commonly used. In the literature,
range has been defined in many ways, for example, the depth at which half of all
incident particles have come to rest. Because of the myriad usages of the term
"range" in the literature, great care must be used to ensure proper interpretation
of the intended meaning

Range shifter

See energy absorber

Range
uncertainty
margin

Distal and proximal margins with respect to the treatment target, to account for
uncertainties in the calculated and/or delivered range of particles for fulfilling
prescribed target doses

Medical Physics, 48 (1), January 2021
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TABLE I. Continued.
Term
(recommended)

Abbreviation/
acronym

Relative
biological
effectiveness

RBE

The ratio of absorbed doses necessary to obtain the same biological effect from
photon beams and proton beams. RBE values vary with organ or tissue, dose,
and a variety of host and treatment factors. Scientific evidence on RBE values in
humans is sparse and highly uncertain. In lieu of observed RBE data in humans,
values have been "recommended" based on available knowledge and subjective
judgement

Relative linear
stopping power

RLSP

The linear stopping power value of a proton beam in some material relative to
the corresponding value in liquid water

Definition

Repainting

A scanning beam technique whereby the beam scans the same volume multiple
times during a treatment with the intent being to average mitigate against the
deleterious effects of any patient motionthat was not fully taken into account in
treatment planning and deliver. The term may also be used for the practice of
scanning each energy layer multiple times before proceeding to the next layer

Residual range

The remaining range of particles at a point of interest, either in the phantom or
in the patient. It is the difference in depths between the range and a point of
interest. Like range, for convenience, it is commonly expressed in residual range
in water

Ridge filter

A range modulator that consists of several ridges and valleys that present
different thicknesses of material to an incoming beam in order to vary its
penetration into the patient

Ripple filter

A range modulator (typically a thin ridge filter) that produces just enough
variation in the light ion energies entering the patient that a reduced number of
accelerator energies may be used without producing ripples in the depth-dose
distribution

Robust
optimization

A method to take into account uncertainties in order to optimize a planned dose
distribution to be resilient to uncertainties in planning and delivery

Robustness

A measure of the resilience of a dose distribution to uncertainties

Scan pattern

A pattern of scanning, including spot positions, energies, and intensities

Scanned beam
Snout

A narrow beam that is laterally scanned to increase the irradiated volume
The most distal part of the treatment head (nozzle) to which interchangeable
beam applicators (e.g., apertures and compensators) are attached and which may
extend toward and retract away from the isocenter. The snout moves parallel to
the central axis of the beam
A proton beamlet at a specified beam energy and lateral position

Spot
Spot profile

The two-dimensional representation of a spot in air or at depth in a medium. Its
significant features are its size, its circularity, and its 1st and 2nd Gaussian fit
parameters

Spot scanning

A technique for creating a large field by scanning a beamlet spot across the
target volume. The beamlet stops at each predetermined point and delivers a
specified dose. Irradiation is usually switched off between the points of delivery

Spot spacing

In scanning beam treatments, lateral spacing between centers of uniformly
spaced spots placed in the target volume

Spread-out
Bragg peak

SOBP

The depth-dose distribution resulting from a combination of a set of quasimonoenergetic beams. The intensities are chosen to produce a region of
longitudinally and laterally flat dose distribution in order to cover a target of a
finite size in depth

Stopping power
ratio

SPR

The stopping power of a medium for a particle of given energy and type is
defined as the average energy loss of the particle per unit pathlength and is
typically expressed in units of MeV/cm. The stopping power ratio is the ratio of
the stopping power of a medium to that of water

Treatment
delivery system

TDS

This term pertains to all components related to the physical and control-system
aspects of delivering proton beam irradiation

Treatment
management
system

TMS

Also known as an oncologic information system. The system responsible for
transferring patient-specific DICOM-RT-ION data from the radiotherapy
planning system to the treatment delivery system. The TMS also serves to
handshake interlock values with the treatment delivery system, record treatment
data, and provide partial delivery recovery

Water equivalent
thickness

WET

The range of a proton beam in water that corresponds to the thickness of a
specific material that leads to the same mean energy loss

Medical Physics, 48 (1), January 2021

Alternate term

Re-scanning

Aperture carriage

Discrete scanning

OIS
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radiobiological aspects of proton therapy are covered by the
dedicated TG-256.5
In general, final acceptance testing should precede clinical
commissioning. This may not always be possible, for example, when multiple delivery or imaging methods are commissioned in sequential order, and some of the commissioning is
not completed until a later date. It is also prevalent for multiroom centers to commission and open treatment rooms in
sequential order to better meet the clinic’s immediate needs.
This report’s scope does not include acceptance testing6–8 or
safety programs (mechanical and radiation), both of which
are required before commissioning. Usually, portions of the
safety testing are required as part of the application process
for the facility operating permission. Detailed information on
acceptance testing, including safety testing, is available elsewhere.9 Also, guidance about the activation hazards associated with proton therapy is available elsewhere.10 Lastly, the
American College of Radiology (ACR) recently published a
document on technical standards on proton therapy.11
Although this report focuses on the clinical commissioning of IMPT, it is not intended to describe IMPT systems in
detail as such information is available elsewhere.2,12 Instead,
the intent is to systematically review the technical commissioning needs of a new proton therapy system, including
ancillary devices such as image guidance (IG) equipment and
the TMS. Very basic systems, such as room lasers are not
covered, and advanced functionality, such as treatment planning techniques, motion management, gating, and target
tracking, are left to future reports. Broader descriptions of
measurement devices for use in proton therapy are available
elsewhere.13,14
One of the main tasks of commissioning is preparing the
TPS for clinical use. Some fundamental physical (non-dosimetric) parameters are required. These values are available
from the equipment vendor.15,16 Commissioning a TPS usually requires two categories of measured data: those specified
by the planning system as being inputs needed for building
the beam models and those used to verify the calculated dose
distributions and refine the beam model, if necessary. When
selecting verification measurements for the beam model and
calculated dose distributions, one should consider the related
limitations, the relevance of the measurement to clinical
applications, the number of measurements, and how the
inclusion of a proposed measurement will affect the time
frame for completing the commissioning task. In general, the
processes of dosimetric measurements and analysis are timeconsuming, especially when discrepancies arise. Monte Carlo
(MC) modeling is used more frequently than in the past to
understand unexpected measurement results and provide a
valuable second reference. Although MC modeling is not
required for commissioning, details of its use are included in
this report because of its potential to reduce error and
increase efficiency. Also, commercial MC dose calculation
for proton beams is beginning to enter clinical practice.
Finally, the report includes details on end-to-end testing and
commissioning recommendations.

Medical Physics, 48 (1), January 2021
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4. EDUCATION, TRAINING, AND TIMING
It is recommended that the commissioning team members
(the team) receive training in proton therapy. The training has
several components.
4.A. Didactic education
Didactic educational material on general proton therapy
principles and practice can be found in various resources.17–20
The team should also ideally attend an educational course
such as the education sessions offered by the Particle Therapy
Co-Operative Group (PTCOG) or the AAPM annual meetings.
4.B. Practical training
Before commencing acceptance testing and commissioning, a vendor’s partner sites can offer observational training
with the advantage of direct experience with the same type of
equipment to be used by the team.
Direct participation in acceptance testing before commissioning is probably of the highest practical operational value.
The user is encouraged to become actively involved during
the acceptance-testing phase taking advantage of the direct
vendor assistance available during the period to assist them
with operating the equipment, whereas, during clinical commissioning, vendor assistance may be limited to an indirect
supporting role. The vendor should train the team in the
specific operation of their proton therapy equipment. Also,
the team should be trained by the vendor on the dosimetry
equipment and systems.
Before commissioning a proton therapy system, it is recommended that the user become fully aware of the features,
properties, and limitations of all sensors and detector (ionization chambers, scintillation systems, films, etc.) used in proton beam measurements. For ionization chamber–based
detectors, the factors to consider are appropriate bias, correction for recombination, and selecting an appropriate size and
shape of chamber.21 Integrating sensors such as film or scintillating systems require care to avoid saturation in high linear
energy–transfer regions,22–24 spatial deviations over the scan
or capture area, and artifacts near the edges.25,26
It is recommended that the new proton beam user setup
the TPS as early as possible for planning practice. Proton
TPSs typically come with installed sample data, which is sufficient to begin rough exercises. MC–generated data (Section 11.G) can provide near realistic beam data27 that can be
verified and/or improved later with commissioning measurements. Given the difficulty of discerning the quality of novice
proton treatment planning efforts, external review by experienced planners is recommended, before a system is first used
to treat a patient. Also, the reviewers, which should be a multidisciplinary team (including radiation oncologists and medical physicists), should review and suggest improvements for
the proposed proton treatment planning policies and
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TABLE II. Example of a commissioning schedule for a one-room IMPT installation. Most of the activities require proton beam irradiations. Some activities not
requiring proton irradiations (†) may be performed earlier in the facility if access is available.
Objective A

Objective B

Objective C

Week 1

Machine dose calibration

Test all commissioning equipment
and setups used†

Week 2

Beam measurements

Daily output check

Week 3

Beam measurements

Image guidance debugging and
optimization†

Week 4

Beam measurements

Image guidance debugging and
optimization†

Week 5

Beam measurements

Week 6

Image guidance debugging and
optimization†

Week 7

Milestone
Dose calibration

Calibrate CT simulator†

2-week clinical machine
stability achieved

Dose modeling

Beam model measurements
completed

Machine-specific quality assurance
development

Dose modeling

Image guidance operating
correctly

Dose model validation

Image guidance exercises†

Week 8

Dose model validation

Image guidance exercises†

Machine-specific quality assurance
development
Machine-specific quality assurance
development

Week 9

End-to-end testing

IROC TLD irradiations

Patient-specific quality assurance
development

Week 10

End-to-end testing

Patient-specific quality assurance
development

Staff training†

End-to-end tests complete

Week 11

Mock treatments of initial patient
types

Staff training

Quality assurance

Clinical commissioning
complete

procedures and a representative sample of plans covering the
intended sites for treatment.

Dose model validated

5. COMMISSIONING A CT SCANNER FOR PROTON
THERAPY PLANNING
5.A. Background

4.C. Timing
The commissioning time required for proton therapy systems is a function of the machine complexity, readiness, and
staff experience. The example presented in Table II shows
how quickly a single IMPT treatment room can be commissioned. The example is calculated based on the experience of
commissioning using 12-hr shifts (with two staff members
per shift) in the treatment room for 6 days each week. It
excludes the commissioning of a nozzle-mounted energy
absorber (EA).
The example can be extended to multiple rooms, where
further efficiency can be achieved if the systems’ calibration
fields are within 1% of each other, the spot profiles match
within 10%, and the range and absolute mechanical alignments are within 1 mm. The methods to achieve “room
matching” relates to the design, installation, and need to be
agreed contractually with the PTS provider and installer.
Matched or “twinned” treatment rooms provide the additional
advantage of seamless patient transfer between treatment
rooms in the event of room maintenance or schedule
demands. Also, it should be noted that when used for clinical
operation, due to reduced room availability times after the
commissioning of the first treatment room is completed in a
multi-room system, that the commissioning of subsequent
rooms may take longer calendar time.

Medical Physics, 48 (1), January 2021

In proton therapy, a CT is used to obtain the TPS’s volumetric patient data; therefore, it is recommended that the CT
scanner used is commissioned as a radiotherapy simulation
scanner (CT simulator). Commissioning a CT scanner for
TPS simulation requires proton therapy-specific items, as
presented in the following subsections. Evaluation of the
imaging dose is also part of the process.28–33 TG-202 discusses the uncertainties associated with the use of a CT scanner in the proton therapy treatment planning process.34
5.B. CTN to RLSP conversion for proton beams
The CT number (CTN) to relative linear stopping power
(RLSP) conversion functions should be determined to provide accurate proton plan optimization and dose calculations.
The three most common types of functions that have been
used to relate these parameters are the following: (a) direct
user input of CTN/RLSP number pairs35; (b) direct user input
of CTN-to–mass density values, followed by the use of a preprogrammed mass density–to-RLSP function36; and (c) direct
user input of CTN/tissue group/mass density triplets that are
then used to calculate the RLSP.37–40 The input requirements
of the TPS determine the type of function used. The CTN
and RLSP measurements of real tissues are difficult to
obtain. Therefore, most clinical facilities have used plastic
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FIG. 1. Plot of relative linear stopping power (RLSP) vs. CT number (CTN),
illustrative of the uncertainty arising from manmade polymer inserts relative
to calculations from ICRU-46 tissues. [Color figure can be viewed at wileyon
linelibrary.com]

tissue substitute measurements to determine the required proton beam energy for the desired range in a medium. A standard phantom should be used, and verification of the CTNRLSP fit from the Imaging and Radiation Oncology Core
(IROC) Houston Quality Assurance Center* is recommended.
As shown in Fig. 1, a plot of the measured CTN/RLSP number pairs for these plastic substitutes does not lie on the function curve for calculations from real tissues, so offsets should
be used to convert the measured data to that of real tissue.35
The most common conversion function used in TPSs is
type (a) given above. The information for this function may
be acquired by several different methods, as described by several investigators for both kilovoltage and megavoltage
CT.41–46 Conversion type (b) is more straightforward as it
only relates CTN to physical density, but the user may have
to manipulate data to have control over the final conversion.
Conversion type (c) is usually used with MC dose algorithms.
The accuracy of the conversion is a current concern in the
field. In an IROC study, a simplified method and phantom
were used to survey 14 scanner conversion functions at ten
proton facilities in the United States.47 Compared to the functions generated using the standard phantom and method, the
RLSPs converted using the facility functions varied by 8%
for tissues within 300 CTN of water and by 16% for lung tissue. For the conversion of low-density immobilization foam,
the facility-to-facility differences were as high as 40%.48
Although individual institutions claim a 1–2% accuracy for
their conversion functions, this study with a standard phantom underscored the difficulty of determining these functions
and their variability. These difficulties further support the
recommendation to use a similar standard phantom for easy
determination of the conversion functions. The IROC is also
pursuing the use of a particular phantom with the eventual
goal of standardization.49
Further advances may be made using dual-, multi-, or
spectral-energy CT calibrations that give an effective atomic
number and relative electron density.50–55 However, these
*

IROC Houston QA Center, M. D. Anderson Cancer Center, Unit
607, 1515 Holcombe Blvd, Houston, TX 77030
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methods are still mostly in the research stage and not yet
implemented in the clinic. In current practice, using singlekV calibration, the resulting conversion functions should be
accurate to within 2% for soft tissues with near unit density.
Other biological tissues with higher or lower density (such as
lung) and high Z (such as teeth), will not fall within this
range.46,56 Note that the uncertainty in converting CTN to
RLSP is only one component of the overall beam penetration
uncertainty. The uncertainty in the CTN itself is typically larger than the conversion uncertainty. Beam delivery inaccuracies also contribute to penetration uncertainty. Also, a
separate conversion function should be generated for each set
of CT scanner parameters (protocols) with different kVp,
scan field-of-view size, and reconstruction kernel.
6. ANCILLARY DEVICES AND MATERIALS
Proton therapy treatments are highly conformal. Any
unplanned change in pathlength due to the presence of foreign materials can cause severe dose and range errors.57,58
Whenever a foreign material is introduced into the proton
beam, it is recommended to account for the resulting change
in beam-path length. Some examples of foreign materials and
strategies for accounting for their range-loss properties are
presented here, with most materials intended for radiation
oncology treatment fabricated from low-density materials.
Even so, lightweight devices may have a water-equivalent
thickness (WET) of several millimeters, which is sufficient to
affect the intended dose distribution if unaccounted for59. In
addition to the discussion here, the reader is referred to the
relevant literature,60–62 specifically TG-176,63 and the AAPM
Summer School Monograph #37, Chapter 18, Immobilization
and Simulation.59
6.A. Treatment tabletops
It is recommended that the alignment, uniformity, and
WET be determined for each tabletop used for therapy. Also,
their mechanical sag characteristics with distributed weights
should be characterized. Because material inserted between
the proton therapy system and the patient reduces proton penetration and scatters the beam, it is recommended that the
effect of the treatment couch be considered in cases in which
the beam passes through it. A further complication arises if
the treatment couch differs from the couch used for TPS simulation.64 Therefore, a set of physical and radiologic tests
should be carried out to ensure the uniformity of the treatment couches to be used. The first step is to acquire a CT
scan of each couch and inspect the image set for inhomogeneities resulting from the fabrication process (there should
not be any). The second step is to obtain a series of WET
measurements at regular spacing through the couch and at
several energies.35 Typically, WET values for commercial
treatment couches used in proton therapy range from 0.55 to
1.2 cm. WET, however, is not energy independent.65,66 The
WET angular dependency follows the inverse cosine function
from the beam incidence relative to the couch’s normal
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vector. Because the function is nonlinear and begins to vary
greatly at high angles, such high angles of incidence should
be avoided. Also to be avoided are the couch edges. Some
TPSs can model the treatment couch in place of the scanner
couch, as part of the patient-plan preparation process. In such
cases, the WET-loss TPS modeling should be verified for the
therapy couch.64
6.B. Immobilization devices in proton therapy
It is well understood by the practitioners of proton beam
therapy that proton beams are more sensitive to patient setup
uncertainties than conventional external beams.67 The sensitivity of proton beam therapy plans to setup uncertainty is
related to the dependence of the Bragg peak dose deposition
curve on depth in the patient. Due to the treatment quality
sensitivity to range accuracy, it is essential to appropriately
select and characterize the immobilization devices used in
proton beam therapy.
6.B.1. Mitigating range uncertainty due to
immobilization devices
Any immobilization device in the beam’s path should be
investigated for its proton stopping power, if possible,
through direct measurement in the beam.68 If the measured
stopping power differs significantly from the stopping power
predicted by the Hounsfield Unit (HU) to stopping power
conversion tables used in the clinic, the immobilization
device must be contoured and assigned a HU consistent with
the measured stopping power. It is well known that HU estimation may become unreliable at distances far from the CT
scanner axis. Therefore, bulky immobilization devices such
as oversized vacuum bags that extend into regions of high
HU uncertainty should be avoided.
Another way in which immobilization devices may contribute to range uncertainty is by introducing sharp gradients
in stopping power in directions perpendicular to the beam
direction. If the patient is positioned differently relative to the
relative position during CT, such an immobilization device
could act as an unintended range shifter, thereby significantly
distorting the desired dose distribution. Therefore, immobilization devices used in the proton practice should ideally be
chosen with rounded edges.
6.B.2. Specialized immobilization devices
Every immobilization device used for external beam radiation therapy should be evaluated for their ability to reduce the
intra- and inter- fractional setup uncertainties. In general,
immobilization devices, both internal and external, should
cause no or minimal imaging artifacts. Additionally, as
described earlier, the effect of the change in the shape, size,
and material in the immobilization devices in the proton
beam’s path can perturb the delivered dose from the planned
dose. Therefore, site-specific immobilization devices need to
be evaluated for their suitability to be used with proton
Medical Physics, 48 (1), January 2021
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therapy during their clinical commissioning. Some of the
commonly used immobilization devices for treating different
sites are described below, with specific recommendations for
their evaluation.
Treatment sites in the pelvis and extremities: It is preferable to keep immobilization devices out of the beam path. In
practice, it is often not possible to do so. For treatment sites
in the pelvis, like the prostate, the devices do not come into
the beam path. However, the vacuum cushion system can
potentially be in the beam path for some non-prostatic sites in
the pelvis and for treating targets in the leg, hand, and pelvic
area for pediatric patients. Therefore, the vacuum cushion stability during treatment needs to be evaluated, and the ability
of the TPS to correctly determine the WET of the material
from CT scans should be evaluated.
Internal immobilization, such as the endorectal balloon
(ERB), is commonly used during prostate proton beam therapy, often in conjunction with fiducial markers, to control the
position of the prostate and rectal mucosa.69 Recently, gels
have become available to separate the prostate from the rectum.70 These devices must be investigated for their effect on
the dose distribution if the proton beam passes through them.
Specifically, the procedure for insertion of ERB should be
evaluated in the initial stage of its implementation with
repeated imaging studies to ensure that the variations in the
position of ERB and volume of liquid material in the ERB
are minimal. The material of fiducial markers should produce
no or minimal imaging artifacts. The spacer gel’s WET
should be measured and should agree with the calculated
value from the TPS from CT images with the gel.
Treatment sites in the thorax and abdomen: Thoracic and
abdominal patients use similar immobilization devices that
may include a sizeable hemi-body vacuum cushion, a wing
board, and a T-bar. The wing board and T-bar are always kept
out of the beam path. The evaluation of the vacuum cushion’s
suitability for proton therapy is already described in the previous section. Implanted fiducial markers are also used to localize the targets in the liver and lung. These markers should be
evaluated to ensure that they cause no or minimal artifacts, and
the TPS correctly calculates the WET of the markers.
A device used as the surrogate of the breathing-related
motion may be required to be placed on the patient. However,
its location is usually away from the beam path. If it happens
to be in the beam path, its WET should be determined by
measurement and be compared with the calculated value
from TPS using a CT scan taken with the device.
The quantification of any residual uncertainties is important for mitigating these uncertainties in the TPS by using
appropriate margins around the target to create planning target volumes or beam specific planning target volumes and
plan robustness analysis. This can be achieved by repeated
imaging studies and a retrospective study of setup images
used for localization before treatment.

e10

Farr et al.: Proton commissioning

Treatment sites in head and neck, and brain: Head and
neck and brain immobilization devices usually include a
headrest, mask, and sometimes a bite block that might require
dental stents. All these devices are typically made of low-Z
materials and do not create any imaging artifacts. The WET
of these devices should be measured and compared with the
values calculated by the TPS from the CT images taken with
these devices to validate the calculation’s accuracy.
6.C. High–atomic number materials in proton
beams
Metallic objects such as dental fillings or implants can
cause CT artifacts. For example, streak artifacts from hip prostheses can lead to range errors of 5–12 mm.71 Solutions proposed to correct these artifacts and minimize the resulting
uncertainties include contour and override suppression algorithms,72 and the incorporation of megavoltage CT for imaging.71 Dual-energy and megavoltage CT can also be helpful in
this regard.73–77 The contour and override solutions are the
most commonly used methods. A structure of the high-density
object is created with the TPS with an assigned HU. If a physical sample of the material can be obtained, a relative rangeloss measurement can be performed by placing the sample
material in and out of the proton field and noting the difference
in range measurements. This is a direct RLSP determination. It
is recommended to override the density of high-atomic number
materials by using a measured RLSP corresponding to the
CTN from the CT-simulator calibration. In some cases, the
RLSP-to-CTN curve should be extended to higher values to
include special materials. It can also be important to contour
and override normal low atomic number tissues with significant imaging artifacts from adjacent high atomic number materials and reassign HU values for them compared to the same
tissues outside regions of heavy metal artifacts.
Although the TPS may calculate a correct beam range
through metal objects, it may still underestimate the lateral
scattering of protons caused by these objects. Unless MC
modeling is used, the user should be cautious when evaluating doses to organs at risk (OARs) located lateral and distal
to the metal objects. When treating through high-density
materials, single-field treatment plans should be avoided.
Because MC dose modeling has recently become available in
commercial TPSs, its use is suggested in these cases.
Based on the results of modeling, suitable margins and an
appropriate number of fields should be used to provide sufficient robustness against range uncertainty and dose shadow
effects.
7. COMMISSIONING IMAGE GUIDANCE SYSTEMS
FOR PROTON THERAPY
Planar kV IG is currently the most commonly used type in
proton therapy. Volumetric kV IG is also used, and its use is
becoming more widespread.78 Other developmental IG or
“direct” image verification systems include surface (or its
Medical Physics, 48 (1), January 2021

e10

surrogate) imaging systems, proton imaging,79–91 prompt
gamma (p,γ) imaging,92–100 and proton-PET (p,β+).101–109 If
any of these complementary systems are to be used clinically,
then special care must be taken during commissioning to
align the complementary system to the standard system. The
present report restricts itself to the commissioning of standard
kV IG systems.
Most of the kV IG systems used in proton therapy communicate directly with the PPS to position the patient daily or
field-by-field. It is recommended that the accuracy of the
PPS and IG system, including the accuracy of isocentric
motion, be verified by acceptance testing before clinical commissioning. Proton therapy IG commissioning aims to
achieve the following: correct spatial orientation of the TPS,
IG, and delivery system for all geometries treated; adequate
image quality with optimized clinical parameters; minimized
doses for the use cases; and sufficient staff experience with
the IG process. Additional verification of the IG system is
performed as part of the end-to-end testing. Useful tools for
commissioning planar and volumetric IG systems are presented in Table III.
Although IG applications parallel conventional therapy,
they are usually different in appearance and sometimes in
operation. Enough time and support should be given to the
therapy staff to become familiar with the IG process. Part of
the process determines the clinical guideline for when the IG
alignment accuracy is sufficient for treatment. A setup accuracy guideline range is recommended that is synchronized
with the treatment plan margins and robustness.
7.A. Planar image guidance
The distances from the source to the isocenter and detector
should be known in terms of their magnification effect.
Images acquired by x-ray systems are typically compared to
reference digitally reconstructed radiographs (DRRs) from
treatment planning.110–112 In some cases, DRRs may be

TABLE III. Image guidance commissioning tools.

Device

Imaging
type

Comments

X-ray test object

2D

Radiographic image quality

2D-alignment test
object

2D

Planar geometric alignment

X-ray source quality
object

1D

kVp accuracy, linearity, and
reproducibility

3D volumetric test
object

3D

Volumetric image quality

3D-alignment test
object

3D

Volumetric geometric alignment

CT ion chamber

3D

CT integral dose (CTDI)

Anthropomorphic
phantom
Laser tracker

2D + 3D

Suitable for proton therapy use

2D + 3D

Optional but helpful
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generated at the imaging console directly from planning
DICOM-RT data. The images are then compared by aligning
the acquired images with the planned DRR images, most
commonly concerning the bony anatomy or implanted fiducial markers. The amount of translational and/or angular
shifting needed to match the images is used to calculate the
correction vector applied to the PPS. After the corrective
movement, the patient position may be verified (or not) by reimaging, depending on the clinic policy. The use of internal
fiducial markers instead of or along with bony anatomy
should be considered part of clinical preparation.113 Markers
come in many varieties: some are bio-oncotic, and some are
simple metallic structures. As there is a trade-off in terms of
visibility and proton dose perturbation, any type of marker
system used should undergo dosimetric and visualization
checks.114–118
An essential task of planar IG commissioning is to verify
its image orientation correctness through the chain. The coordinate systems can vary between the planning, delivery, IG,
and treatment management systems. Although usually confirmed earlier as part of the facility integration software-connectivity testing during end-to-end acceptance testing, it is
recommended that the correct display of coordinate-based
image data be verified as part of the IG commissioning. It is
recommended that all clinical geometries intended for use
have their IG process and correctness verified. Examples
include verifications of different patient orientations, such as
prone/supine and feet-first or head-first. Special care must be
taken when using unusual patient positions, unusual gantry
or couch angles, or a treatment chair. The image geometry
correctness should be verified for potential up–down, left–right, and mirroring errors. Once the planar IG system is processing and displaying information correctly, the registration
process should be tested. For this purpose, a phantom may be
intentionally translated and rotated away from its reference
position. After that, the IG system should accurately indicate
the displacement. During commissioning, it is especially
important to perform this verification over the range of translations and rotations to be used clinically. Specifically, small
translations of 1–3 mm, isocentric rotations, and more substantial translations associated with field junctions should be
verified and their uncertainties incorporated into the clinical
process. The planar IG system can be used to correct for
couch sag relative to the planned geometry. The couch-sag
behavior needs to be understood under various loading and
orientation conditions to produce clinical use guidelines for
the IG process.
The non–proton-specific extensive IG tests required for
commissioning and are also used with other teletherapy
modalities can be found in existing photon beam quality
assurance reports.119,120 These reports provide information
about tolerances for quality assurance and control, including
kilovoltages, mAs, low- and high-contrast resolution with different phantoms, and radiography tests. The dose associated
with clinical imaging techniques must be determined, especially for pediatric cases. For any imaging system, the isocenter congruence should be re-verified (after acceptance
Medical Physics, 48 (1), January 2021
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testing), particularly in comparison to the proton isocenter
and the mechanical isocenter.121,122
7.B. Volumetric image guidance
Volumetric IG offers the possibility of soft tissue as well
as bony alignment. Additionally, the volumetric images might
be used for dose recalculation123–125 or adaptive purposes.126
These functionalities are driving the integration of volumetric
IG via cone-beam CT (CBCT) or CT on rails. The CT-onrails systems can be placed inside127,128 or outside128 the
treatment room. Volumetric IG can be combined with planar
IG through the generation of DRRs. Commissioning CTbased IG systems for radiotherapy is discussed in detail in
AAPM TG-179129 and the previous TG-104 report.120 Volumetric IG geometric accuracy tests should be completed as
part of acceptance testing. Because of the dynamic nature of
volumetric image-acquisition systems, the geometric accuracy should be evaluated compared to static planar systems.
Hence, re-verification (post–acceptance testing) of the geometric and image accuracy should be performed during commissioning using the volumetric tools listed in Table III. The
dynamic nature of CBCT systems also contributes to the risk
of physical injury, especially in proximity to the nozzle, and
more so with the use of a movable accessory mount. Collision detection and avoidance systems can reduce the motion
injury and PTS damage risks, and if available, should be verified as part of acceptance testing.
It is crucial to commission the volumetric IG system for
clinical use cases. The field-of-view (FOV) or length-of-view
limitations of the volumetric imaging system may determine
the clinical range of use. For example, small FOV images
may be suitable for isocenter/target alignment verification but
inadequate for skin/outer tissue geometry changes that may
cause additional range changes relative to the target/OAR. If
imaging is to be performed away from the treatment location,
then geometric accuracy verifications should be provided
over the relatively long transfer distances.128 This should also
be performed for non-coplanar setups.
8. TREATMENT MANAGEMENT SYSTEM
COMMISSIONING
8.A. Background
Treatment management systems play vital roles in modern
radiation oncology.130 Their primary functions are to record
and verify patient treatments. It should be noted that, for
some TMS systems, the proton version of the TMS can differ
significantly from its photon counterpart, and specific tests
should be designed to test these aspects. The TMS either
shares a database with the TPS or has its database. When the
databases are separate, the TMS communicates with the TPS
by using DICOM-RT, an extension of DICOM with radiation
therapy information objects established in the mid-1990s.131
To support general ion-based treatment planning and delivery
processes, Working Group 7 of the DICOM Standards
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Committee added DICOM-RT-ION, including RT-ION Plan
and RT Ion Beams Treatment Record, to DICOM in Supplement 102 in the mid-2000s.132 Although vendors provide
DICOM conformance statements for their products, these
statements are not a guarantee of compatibility between various devices, and potential non-compliance should be
addressed during acceptance testing. Integrating the Healthcare Enterprise in Radiation Oncology, an American Society
for Therapeutic Radiology and Oncology initiative seeks to
achieve better interoperability in a multi-vendor clinical environment through the coordinated use of established standards,
such as DICOM and HL7.133,134
8.B. Commissioning
During commissioning, the TMS functionality should be
verified concerning correct data transfer and recording. There
are several aspects to this verification. First, it should be verified that the planned treatment fields are downloaded into the
TMS with the reference images as part of a DICOM-RT-ION
plan. Second, the treatment-field parameters communicated
to the delivery system for interlock checking should be verified at the delivery system hardware level. If used, ancillary
devices such as apertures/compensators and EAs should also
be interlock verified based on the TMS. Such interlocks must
be present. They should be validated in the therapy control
system too, that is, the interlocks should be verified by both
the therapy control and TMS. Additional examples are nozzle
settings, gantry angles, and couch angles. General delivery
system interlock parameters such as proton range (planned vs
machine delivery setting) also need to be set in the TMS. The
IG data recorded at delivery are contained in the RT Beams
Treatment Record and should be uploaded into the TMS as
part of the treatment record and offline review, if desired.
The images’ orientation should be verified in the TMS and
should match the correct orientation in the previously validated IG system (Section 7). The treatment record that
includes verification images (together with the applied relative couch offsets) should also be checked. The recording and
subsequent recovery of partially delivered fields should be
verified using the TMS. Finally, it is recommended that the
entire TMS-related workflow of patient verification, barcode
scans (if used), patient setup, treatment delivery, and dose/
MU/beam geometry/overrides and partial delivery be verified. This verification should be completed before end-to-end
testing (Section 12).
9. PROTON MACHINE ABSOLUTE DOSE
CALIBRATION
PTS output calibration to absolute dose is a central clinical
commissioning task. The new user is faced with how to implement the biological effectiveness (RBE) factor required for
proton therapy and implementing the calibration protocol with
decisions on the reference field and ionization chamber used.
The needed details are presented in the following sections.
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9.A. Radiobiological effectiveness factor
This report addresses only physical dose calibration. After
physical dose calibration, an additional relative RBE factor is
required. The currently accepted RBE factor is 1.1, but this
represents only an average value.135 The user is cautioned to
ensure that the RBE factor is only applied at a single point
(not twice) in the treatment workflow. The most common
places to use the factor are in the TMS or the TPS. Applying
the factor in the TPS has the advantage that the planner and
the radiation oncologist are provided with dose distributions
in terms of Gy (RBE).136 Either way, a single approach
should be selected and applied consistently within the institution. For additional detailed information on the selection and
implications of the RBE factor.5
9.B. Calibration protocol
Absolute dose calibration methods have evolved and continue to evolve for proton therapy. Measurement with tissueequivalent detectors, dose to tissue, Faraday cups, and
calorimetry have historically been performed, and most
recently, dose to water determined using an ionization chamber calibrated in a 60-Co beam,137,138 have been included. It
is currently recommended that reference dose calibration be
performed according to the N D,w,Q0 -based method of calibrated ionization dosimetry presented in TRS-398.139 The
ionization chamber should be calibrated by an Accredited
Dosimetry Calibration Laboratory (ADCL). Optionally, it is
possible to further reduce the dose calibration uncertainty by
using calorimetry.140–144
9.C. Reference ﬁeld and point of measurement
Critical user choices in the calibration process are the
determination of the type and size of the reference field to be
used and the selection of the measurement point within the
reference field. The reference field could be either a broadscanned series of closely spaced individual monoenergetic
beamlets (referred to in this section as a pristine beam but
sometimes termed a monolayer) or a spread-out Bragg peak
(SOBP) delivery. SOBP calibration is predominant and usually employs a 10 × 10 × 10 cm3 cubic field at a selected
depth. Typically, the cubic field placement in depth is chosen
to be representative of the “average” treatment field range
intended for the practice. Alternatively, when the calibration
is performed in a monoenergetic pristine beam, the relatively
flat plateau region is used. In this case, because of the ionization chamber–specific factors that depend on the measurement-point depth, depths of at least 1 cm in water are
recommended. A uniform set of equally weighted spots is
scanned for the single-energy (pristine) field and scanned
monolayer deliveries. The scanned monolayer approach
potentially introduces measurement uncertainty from the ionization chamber position concerning field ripple. For this reason, it is recommended to use a spot spacing that reduces the
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field ripple to <1% in the vicinity of the measurement location.145
9.D. Ionization chamber choice and associated
uncertainties
The choice of a suitable ionization chamber for the absolute dosimetry provides a sound basis for the task. This
requires knowledge about the chosen absolute dosimetry protocol, the user’s implementation of the protocol, and the
beam properties of the system to be calibrated. This generally
means selecting a suitable size and shape of the dosimeter or
applying correction factors of potentially greater magnitude,
with their corresponding uncertainties.
Three sources of ionization chamber uncertainty can be
considered contributing to the total absolute dosimetry of the
proton beam: 60-Co calibration uncertainty, long-term stability uncertainty, and the uncertainties arising from TRS-398
calibration of the proton beam using the specific ionization
chamber type.
9.D.1. 60Co-ionization chamber calibration
uncertainty
Uncertainty arises from the calibration of ionization chambers at an ADCL. When using an ADCL calibrated cylindrical ionization chamber with TRS-398, the dosimetric
uncertainty reportedly results in a 1.7% dose uncertainty,
whereas using an ADCL calibrated plane-parallel chamber
results in a 2.1% dose uncertainty. The difference in the
reported uncertainties results from the 60Co calibration of the
ionization chambers in the standards laboratory reference
60
Co beam.
9.D.2. Long-term ionization chamber stability
uncertainty
Mechanical properties can contribute to the uncertainties,
including the mounting of the central electrode. The long-term
stability of cylindrical chambers has been observed to be better
than that for plane-parallel chambers in electron beams, with
the differences in relative calibration coefficients being typically less than 0.1% over 5 years, whereas 0.2–0.3% was found
to be typical for the types of parallel-plate ionization chambers
used for proton therapy dosimetry.146
9.D.3. Calibration ionization chamber choice and
absolute dosimetry uncertainties
When using TRS-398 with a calibrated ionization chamber, it is reportedly possible to achieve a total absorbed dose
uncertainty for ionization-based absorbed-dose determinations based on calibrated ionization chambers of 2.6%.136 It
is also good practice to perform the calibration dosimetry verification or cross-calibration with two independently calibrated ionization chambers to mitigate any systematic error
between chamber calibration dates.
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Two practical sources of measurement uncertainty can
impact the desired uncertainty magnitude: the effective point
of measurement and the ionic recombination.
Subjectively, small-diameter plane-parallel chambers have
a distinct measurement point in proton beams, and the effective point of measurement accuracy is arguably improved
compared to cylindrical ionization chambers. Objectively, it
has been reported that following the TRS-398 recommendation of positioning the reference point of a cylindrical chamber at the reference depth can lead to a systematic
underestimation of absorbed dose for monoenergetic beams,
especially for lower energy proton beams. Considered to be a
dose gradient effect resulting from the effective measurement
point of cylindrical ionization chambers, it is less evident
with use in SOBPs.147
In general, the instantaneous dose rate from IMPT systems
can be relatively high as the narrow proton beamlet is
scanned across an ionization chamber. High instantaneous
dose rates can elevate ion recombination in the collecting
gas, especially for larger volume chambers, including cylindrical chambers.148 Therefore, care should be taken about
recombination factors that depend on the ionization chamber
size, bias, and dose rate. Specifically, higher recombination
correction factors can be expected for larger-volume cylindrical chambers (Farmer chambers) with IMPT cyclotron- and
synchrocyclotron- vs synchrotron-based beams. The combination of IMPT systems possessing higher instantaneous dose
rates from high flux accelerators with small spot sizes further
exacerbates and the ionic recombination effect with larger
ionization chambers.149 Indeed, higher instantaneous dose
rates and smaller spot sizes are a growing trend in proton
therapy.
Generally, and historically, Farmer-type cylindrical chambers were commonly used for absolute dosimetry protocols
associated with the “double scattering era.” But, because of
the issues relating to uncertainties of their use for IMPT
dosimetry, the usage trend has been and is expected to continue toward small volume parallel plate chambers in the
absolute dosimetry role for IMPT. Specifically, in some cases
of combined ionization chamber choice and PTS, the
required correction’s magnitude due to ionic recombination
may exceed 1% in higher flux beams. It is recommended by
this group not to exceed 1% correction for ionic recombination.
Ionic recombination must be characterized experimentally
by the end-user, but contributing are the design, fabrication,
and assembly of the central electrode. Deviations can result
in low E field strength in small portions of the sensitive volume. In a guarded plane-parallel ionization chamber, the sensitive volume has a uniform and strong E field, which avoids
or minimizes most of the recombination issues mentioned.
They may be less susceptible to recombination in high-flux
IMPT systems. Furthermore, it is essential to understand the
dosimetry system recombination behavior with the specific
PTS. It is possible to gain understanding by measuring the
entire response curve with multiple voltages and graphing the
results for extrapolation.150,151 But for commissioning, the 2-
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voltage determination of the recombination factor152 is
widely used, although its underlying assumptions have been
challenged for high instantaneous dose rate systems.153
Increased chamber bias (within the chamber-bias specification range) may also reduce recombination in some cases.
Finally, polarity corrections must also be considered, but they
are typically negligible in proton beams for plane-parallel
chambers.154,155
In summary, the uncertainties associated with absorbed
dose calibration of proton beams can be classified as intrinsic
and practice dependent. The inherent uncertainties stem from
the physical characteristics of the ionization chamber and its
60
Co calibration. The principal practice dependent uncertainties are associated with the accuracy of the effective point of
measurement and the corrections for ionic recombination in
the ionization chamber with an applied electric field. For
these reasons, this group’s recommendation is to use a calibrated, guarded, plane-parallel chamber for IMPT absolute
absorbed dose calibration.
9.E. Interfacility comparisons and remote auditing
Consistency in calibration accuracy among proton therapy centers is vital if their clinical outcomes are to be
compared. In 2008, after earlier efforts to make such comparisons,156–158 the IROC launched a program for proton
center dose verification and monitoring that is now widely
used.159 The National Cancer Institute (NCI) mandates
participation in the program by those proton therapy institutions wishing to participate in NCI-sponsored clinical
trials. Indeed, the IROC credentialing program is a valuable resource, and it is recommended that its services
form part of the proton therapy system commissioning
effort. Specifically, it is recommended that the machine
dose calibration for the reference field be confirmed
through the IROC before the first patient treatment.
10. OUT-OF-FIELD DOSE FROM PROTON
THERAPY
Physicians treating patients with radiation need to assess
the patient’s secondary cancer risk from doses delivered to
normal tissues outside the primary treatment field.160–166
Except for a new type of system, or significant system modification where the proton beam is partially blocked in the
treatment room as an example, measurements for out-of-field
dose characterization are not necessarily required for clinical
commissioning. However, it is recommended that the clinical
staff be aware of the out-of-field dose magnitudes and distribution for their system. The following serves as an overview
of the topic.
The out-of-field dose can originate from within the patient
or from the radiation head (i.e., from stray radiation), the
accelerator, or the energy selection system, depending on the
amount of shielding provided. Generally, stray radiation (including that of neutrons) is a consideration in beamline
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design.167 The latest IMPT scanning systems provide lower
out-of-field doses than previous PTSs.168,169 The planners
and oncologists should be aware of these results as part of the
clinical treatment planning process. But it is too complex and
time-consuming to assess stray radiation exposures as part of
routine clinical treatment planning. If desired, specific tests
can be performed to evaluate out-of-field dose values.170
Also, Moyers et al. have described various measurements that
can be made for this purpose.171 The subject of the out-offield dose is also related to the treatment of pregnant patients
and patients with implanted cardiac pacemakers and defibrillators. Published data on the comparative out-of-field dose
from proton therapy are helpful for the assessment,168,172–175
and the management of proton therapy patients with
implanted cardiac pacemakers and defibrillators is specifically addressed in TG-203.176
11. RADIOTHERAPY PLANNING SYSTEM
COMMISSIONING
This section on IMPT TPS commissioning includes a
description of the most common type of IMPT dose
model (provided to promote basic understanding), the
specific measurements required to form the dose model,
and different special features of IMPT systems and their
applications. Because MC methods are expanding in use,
they are also discussed.
IMPT systems, in contrast to previous types, use a building block approach to form their field. The building blocks
are the individual "beamlets." Therefore, much of the effort
in IMPT commissioning is in measuring and characterizing
the beamlets for the complete range of energies and any beam
modifying devices employed. The other elements of IMPT
dose models and measurements are the energy settings, virtual source-to-axis distance, and effective source-to-axis distance, which are standard for radiotherapy machines.
However, the fundamental difference in field generation
results in some different uncertainties.177 With the buildingblock approach, the concern is that relatively small errors
under certain conditions may sum to larger errors during field
delivery as the "blocks" sum together.
An example of this is the spot halo dose that, if unaccounted for, can lead to dose calculation errors more than
3%/3 mm for an excess percentage (>5%–10%) of points
tested within fields.178,179 This concern guides the commissioning effort to reduce errors in measurement and calculation as much as possible for the spot profiles and IDDs. With
the resulting high-quality building-block data and dose
model, IMPT commissioning should follow the generation
and verification of uniform and non-uniform fields that are
representative of the fields to be treated clinically.
MC methods are increasingly serving in two general areas:
generation, verification, and correction of commissioning
data needed as an input for the TPS dose model, and as a
dose model directly internal or external to the TPS. Both
applications are discussed here.
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11.A. Dose modeling for treatment planning
11.A.1. Analytical dose model representation
Intensity modulated proton therapy dose modeling is typically performed using a pencil-beam algorithm. The elemental dose to a point from a proton pencil beam centered at
ðx0 , y0 Þ can be expressed as




DPB ðx,y, zÞ ¼ C zeq , x0 , y0  O zeq , x  x0 , y  y0 , (1)
where zeq is the water-equivalent depth of the pencil beam
evaluated at the plane of calculation. The central-axis term C
represents the depth dose, and the off-axis term O models the
radial spread. The total dose for each point inside the calculation volume is computed by adding all the pencils’ contributions within the beam.
The spot fluence profile can generally be modeled by a
single Gaussian, with σx and σy characterizing the x- and ydistributions, respectively. The spot sizes (x and y) are plotted
against the beam axis (z) and fitted to the following function180:
rﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
A
C
þ B  z þ  z2 ,
f ð zÞ ¼
(2)
2
2
where A, B, and C are the free-fitting phase space parameters
used to model the beam propagation, and A2 represents the
variance (σ2 ) values of the spots. The sigma values tend to
vary with the gantry angles (typically within 5%), but TPSs
may not model such dependency. In such a case, the average
values from the measurements are used.178 Beam spot shapes
can deviate from the ideal Gaussian form, primarily because
the multiple Coulomb scattering proximal to the nozzle exit
is dependent on system design choices such as beam optics,
accelerator properties, and scattering devices such as monitors. In contrast, the MCS distal to the nozzle is due to the
effect of beam-modifying devices. To adequately model the
in-air fluence in this situation, multiple Gaussian modeling
has been introduced.178,181
11.A.2. Modeling low-dose Halo
Large-angle scattering and secondary products from
nuclear interactions in water result in a low-dose halo centered on the narrow proton pencil beam. In some cases, this
low-dose envelope can extend to a radius of up to 10 cm, and
radial contributions from many neighboring pencils within a
scanned beam can add up significantly. As much as 15% of
the dose can be attributed to the beam halo.179 This effect
was not modeled in early scanning-beam algorithms. The
most noticeable consequence is a systematic dependence of
the observed dose as a function of the size of the target volume. Pedroni et al. proposed modeling the beam halo by
using the following empirical formula179:


Dðx, y,wÞ ¼ TðwÞ  ð1  f NI ðwÞÞ  GP2 x, y, σp ðwÞ
(3)
þf NI ðwÞ  GNI
2 ðx, y, σNI ðwÞÞ,
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where Dðx,y, wÞ represents the dose at a point in water at a
depth w; TðwÞ is the integral dose at depth w;f NI ðwÞ is the
fractional contribution
 at depth that
 is assigned to the nuclear
interactions; and GP2 x, y,σp ðwÞ and GNI
2 ðx, y,σNI ðwÞÞ are
the two-dimensional Gaussian functions for the undisturbed
primary beam and the low-dose envelope distributions,
respectively.
11.A.3. Accuracy and limitations of analytical dose
algorithms
Analytic dose algorithms (ADCs), commonly known as
pencil beam algorithms,180,182,183 are widely used for proton
therapy treatment planning. Clinical implementation of
ADCs is often optimized for speed rather than accuracy to
achieve a reasonable calculation time. Users, therefore,
should review and evaluate the accuracy specific to their clinical needs. For efficiency, Schaffner et al180 uses an in-air fluence based calculation model. In the presence of a
compensator, the perturbed fluence distribution due to scattering is accounted for according to the thickness profile.
Changes in the energy distribution of the scattered protons,
however, are ignored. This approximation can lead to significant errors near the vicinity of a sharp gradient, especially
towards the end of the proton range. Analytic dose algorithms
typically project the range based on the water equivalent
depth in the patient to estimate the lateral spread at a given
depth, ignoring the relative position of the inhomogeneities
to the Bragg peak. For complex geometries and density variations such as at bone-soft tissue interfaces, ADC, given its
limited ability in modeling multiple-Coulomb scattering,
often fails to correctly predict the effects of range degradations and widening of the distal fall-off. These observations
are evident in comparative studies using MC simulations.184,185 Underestimation of doses to critical structure distal to the target, especially in low-density regions, has also
been shown.186 The range uncertainties in the calculation and
the impact on dose accuracy are site-specific. In a study on
five clinical sites, ADC was found to overestimate the tumor
dose by 1–2% on average.187 For complex geometries such as
in head and neck and lung, approximations in ADC and its
limited ability in modeling multiple-Coulomb scattering can
lead to geometric miss from overestimating the range or predicting unrealistic dose homogeneity caused by underestimation or overestimation of scatting effects in tissue. For these
clinical sites, advanced methods, such as MC simulations,
can be beneficial.188 MC calculations are also preferred over
ADCs for dose calculations with IMPT systems degrading
energy in the nozzle.
11.A.4. Monte Carlo as a dose model for treatment
planning
Recently, several commercial TPSs have released MC
dose calculation algorithms for IMPT. Due to their potentially
increased accuracy over analytical algorithms,189–191 the use
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of MC dose calculations is expected to increase in routine
clinical practice. Also, as these implementations are dedicated for treatment planning purposes, they are significantly
faster than current general-purpose research codes, making
their use in a clinical environment more attractive than
before. In practice, MC calculations are most beneficial when
calculating dose when beam-modifying devices such as EAs
or apertures are used, and in planning cases involving inhomogeneities. Having the MC calculation available also
enables exploratory calculations in addition to physical dose
such as linear energy transfer and its variants. Finally, if a
MC dose model is to be used clinically, it must be commissioned and verified. Verification can follow as with analytical
algorithms (Section 11.F), including beam modifying devices
and inhomogeneous materials. The MC dose model’s verification is typically more straightforward in these particular situations because a closer agreement with physical
measurements is easier to achieve than with more limited
analytical algorithms.
11.B. Apertures and energy absorbers
Although IMPT usually operates without the need for
physical beam modifying devices, the devices are sometimes
needed. Most commonly, EAs, sometimes termed as range
shifters, are used to produce lower (typically < 70 MeV)
energies. Physical apertures are also coming into use for
IMPT. Because the physical devices produce secondary scatter, their dose modeling is complicated. Accurate dose modeling of large-angle scattering in an IMPT beam from high-

density beam modifiers is expected to require multiple Gaussian pencil-beam models192 or MC simulations.
11.C. Dose normalization to absolute dose
Planning for IMPT requires ab initio physical dose correlation to absolute dosimetry (Gy/MU). This correlation can
be accomplished by using parameterizations and an empirical
model of the low-dose halo. A dose model based on first
physical principles has been shown to predict the absolute
dose delivered by the line-scanning system of the Paul Scherrer Institute.179 The dose is normalized to the number of incident protons in the unit of Gy mm2 per giga-proton. It can
then be converted to Gy mm2 per MU after calibrating the
MUs using a standard protocol (Section 9). Note: the conversion of Gy mm2 per giga-proton to Gy mm2 per MU is
energy-dependent. Given the total dose and each spot’s relative weight in the plan, the MU for each spot can then be
determined.193 These developments form the basis for the
current TPS calculated dose correlations to measured absolute dosimetry. The dose per MU is also affected by the presence of an EA. Fluence reduction from EA out-scatter should
be evaluated with a series of Gy/MU measurements compared to the open field results.
11.D. Dose model data acquisition
For dose modeling, the TPS requires a set of beam measurements that are described in this section. Each type of
measurement requires a specific set of equipment, as detailed
in Table IV.

TABLE IV. Typical dose model measurements and methods for intensity-modulated proton therapy commissioning.

Type

Modeling (M) calibration
(C), or verification (V)

Integral depth dose (IDD) with and
without range shifter(s)

SOBP depth dose in water

M

C, V

IMPT method and materials
A large-diameter parallel-plate chamber scanned along a single central beamlet in a water
phantom. Monte Carlo corrections are usually required for all current methods.188
Although MLICs are useful for quality assurance, they are not recommended for IDD
acquisition for the TPS modeling need
Parallel-plate ionization chamber in a scanning water phantom. Change the setup
geometry to each different SOBP center

Spot profiles X/Y with and without
energy absorber(s)

M

Film or a scintillation detector. Measure across the energy band in multiple planes
transverse to the central beamlet axis at, proximal to, and distal to the isocenter. The film
and scintillation detector need to be validated for use in the scanning beam, avoiding
saturation or quenching

Virtual source-to-axis distance [X] in
air

M

Scanned proton-field film measurements. Defined as the physical magnet center. Verify
with back-projection of in-air 50–50%radiation field widths along the central axis

Virtual source-to-axis distance [Y] in
air

M

Same as above; VSAD(X) ≠ VSAD(Y)

Dose halo

M

Superposition measurements of an individual beamlet or peripheral scans around a central
measurement point in air

Proton dose per MU density [Gy
mm2/MU] calibration per energy

C

A single monoenergetic fixed beamlet or scanned beamlets delivered to a large-diameter
parallel-plate chamber or small-volume ionization chamber, respectively, fixed at a depth
of 1–2 cm in a water phantom

Lateral dose profiles at depth

V

Scan at multiple depths Small-volume cylindrical ionization chamber in a scanning water
phantom for integrated point measurements, or film, or scintillating detector. Change
setup geometry to each different SOBP center. Measure at multiple depths
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11.D.1. Integral depth-dose measurement, scaling,
and corrections
Integral depth-dose (IDD) representation requires a multistep process, including measurement, curve corrections, and
dose scaling.
Integral depth-dose measurement: All of the system energies should have been verified as part of the acceptance testing. Commissioning of the TPS requires accurate
measurement of a subset of these energies. For systems
selecting their energy in or near the accelerator, the IDD
scans are typically measured for model data input in 10 MeV
steps. Systems degrading energy in the nozzle may rely on a
single maximum energy IDD if the TPS adequately models
the nozzle contained binary range degrader.145,194 In this case,
additional IDD verification measurements are needed (Section 11.F). Static, monoenergetic beamlets should be delivered for the IDD measurements. The IDD measurements
should be performed with a large-diameter plane-parallel ionization chamber with its build-up values verified by the user.
Commercially available large-diameter ionization chambers have an active cross-section of 8.4–15 cm. A scanning
water phantom with sub- millimetric positioning accuracy
should be used. Geometrically, all the IDD scans should be
performed at a fixed source-to-surface distance. The spacing
of the measurement points in depth will be non-uniform. It is
necessary to adjust the measurement step size to <1 mm to
resolve the Bragg peak adequately.
Integrated depth-dose curve corrections: Depending on
the system lateral beam dimension provided, the incident
energy, and the depth of measurement, the ionization chamber area may or may not be sufficiently large to acquire the
entire beamlet dose. MC simulations are commonly used to
assess this situation and then correct the measured data if
needed.195 In practice, the magnitude of the required
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correction depends on the system spot size and the diameter
of the plane-parallel chamber used to collect the IDD curve
data. A generic example of the relationship for a 4 mm–beam
sigma system correction factor with varying chamber diameter is shown in Fig. 2. Specific examples can be found in the
literature.196,197 Because only the plateau portion of the pristine Bragg curve requires correction, it may be easier to substitute the MC-derived curves once they have been
normalized to measured peak values. The scaling of measured data by a calculated specific correction factor has also
been reported.178
After calibrating MC-generated IDDs measured data, they
may be preferred as the commissioning data inputs for the
TPS because of the improved accuracy and smoothness of
the data compared to specific physical measurements.4,178
Integrated depth-dose scaling: Because IDDs are relative
measurements, they should be scaled for each energy as a
function of the MUs (Fig. 3) or the number of protons, usually in 106 or 109 quanta, million protons (Mp), and giga-protons (Gp), respectively, according to the TPS requirements.
There are two approaches to scaling: one using a large-diameter plane-parallel ionization chamber with static,
monoenergetic pristine beamlets; the other using a Farmer
chamber with scanned, monoenergetic pristine fields (monolayers). According to the Fano theorem, the two approaches
should give equivalent results.198 In either case, the ionization
chamber used should be ADCL calibrated or cross-calibrated
to an ADCL calibrated chamber in a wide, flat, photon or
proton field. It is recommended that the scaling measurements be performed at shallow depth in a water phantom.
Water measurement depths of 1–2 cm are suggested so that
(a) the entire energy range can be covered at a single physical
position, and (b) low-energy secondary protons (and stray
radiation) contribute to a limited degree. Because non-primary radiation is dependent on the delivery system, it is suggested that MC modeling can be used to characterize this
radiation and guide the choice of measurement depth. The

FIG. 2. Monte Carlo–determined missing halo dose percent depth-dose (PDD) correction factors at 10-cm water depth for a generic 4-mm spot sigma in air at
221 MeV as a function of the plane-parallel chamber integrating diameter. [Color figure can be viewed at wileyonlinelibrary.com]
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dose algorithm. As discussed in Section 11.A.2, spot halos
can affect the dose calculation accuracy. After dose modeling
with the TPS, verification (Section 11.F) is needed. Should
adjustment to the dose model be required, the spot halo contributions should be re-evaluated and adjusted if necessary.178,202
11.D.3. Virtual source-to-axis distance

FIG. 3. Measured relation between dose and machine monitor units for 96
energies from a synchrotron-based proton therapy system. The measurements
were performed at a constant depth of 2 cm in a water phantom using an 8.4cm diameter calibrated ionization chamber (Bragg Peak chamber, PTW, Freiburg, Germany). The 96 data points correspond to individual synchrotron
"energy tunes"; cyclotron-produced data would appear smoother as a result
of continuous energy selection. [Color figure can be viewed at wileyonlinelib
rary.com]

modeling goal is to determine the optimal measurement point
where beam delivery induced low-energy secondary protons
are stopped ahead of the detector while minimizing the
amount of high angle MCS protons in the phantom proximal
to the detector. Practically, this is within the range of 1–4 cm,
and most typically 1–2 cm. After completion of these steps,
the IDDs may be imported into the TPS for modeling.
11.D.2. Spot proﬁles
It is recommended that the lateral fluence distribution of
the central-axis beam spot in air should be measured in the
isocenter plane and at several distances proximal and distal to
the isocenter plane along the beam axis (e.g., at 10 and
20 cm). It should also be evaluated in various radial directions to characterize the circularity of the spots and the gantry-angle dependency of the spot axes. The user should be
aware that low-level spot fluence (“halo”) extends far away
from the spot axis. Consideration should be given to this
aspect. Following the “building block” analogy (Section 11),
the small components of spot fluence may sum to be significant for fields containing a high number of spots, depending
on the magnitude of the tails. A superposition technique is
usually applied because the halo portion of a spot fluence has
a very low magnitude, practically 1/1000 of the maximum
central beamlet value. By pairing measurements in superposition, one with a lower delivery magnitude for the central portion and the other with a higher delivery magnitude for the
peripheral (halo) portion, the combined measurement’s
dynamic range can be extended as necessary. Both multi-element detectors and film have been used in this manner.179,199–201 Spot halo analysis requires logarithmic plotting
to observe the tails. The spot profiles serve as inputs for the
Medical Physics, 48 (1), January 2021

With IMPT systems, there are usually two VSADs, one for
each scanning direction [VSAD(X) and VSAD(Y)]. Usually,
the VSADs can be assumed to be the distances from the
respective scanning magnets’ centers. The vendor will supply
these values. The VSAD(s) of the magnet centers should be
verified using individual scanned, monoenergetic pristine
fields (monolayers) delivered at low, medium, and high system energies with in-air back-projection film or scintillation
detector irradiations at several positions along and perpendicular to the central beam axis of 50–50% radiation field
widths.203

11.D.4. Energy absorbers
The function of an EA is to reduce the range of the protons
passing through it. This functionality is needed for treatments
that require lower energies. Because EAs are a significant
scattering source, an additional set of spot profile and IDD
measurements are necessary for the TPS data modeling.
11.D.5. Ripple ﬁlters
Introducing a ripple filter requires additional commissioning. In part, this is because ripple filters rely on a specified
drift distance between the filter and the intended delivery
point, usually the isocenter. The region in which the ripple
filter effect is acceptable should be determined. Because the
beam properties are modified by the filter, using one usually
requires specifying an additional treatment machine in the
TPS.204 Like EA modeling, ripple-filter dose modeling is
currently being improved in commercial TPSs.

11.D.6. Apertures
The use of an aperture can reduce the penumbra from
IMPT systems with larger spot sizes or when an EA is
used.205–208 Apertures must be thick enough to stop the incident protons. Practically, apertures are indicated for use for
lower energies, and the maximum energy allowed corresponding to the equivalent aperture thickness should be fixed.
The use of an aperture increases the secondary particle (neutron) out of field dose, and the amount should be known.
Dose modeling when including beam scatter producing
devices and combinations of beam scatter producing devices
such as apertures, and EAs is more challenging than for
“pure” scanning. Therefore, the TPS must be evaluated for
suitability for purpose. High-performance analytical dose
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algorithms207 or MC dose algorithms208 are usually required.
In-air penumbra data is needed for analytical dose modeling,
typically using a half beam block or field edge measurements.207 Film or a scintillating detector should be used to
measure the penumbra at the isocenter and several proximal
and distal planes at distances ranging from −20 to +20 cm
from the isocentric plane. Alternatively, a pinpoint ionization
chamber may be used.207 Depending on the clearance with
the aperture mounted, the proximal plane distances may be
reduced to accommodate the geometry. The penumbra measurements should be performed over the range of energies to
be used with the apertures at maximum of 30 MeV intervals.
It is recommended that after dose modeling, the model is validated using a mix of rectilinear and patient fields.207 The validation should be performed at multiple depths (usually two
or three) in water for each field.
11.E. Monitor unit determination
The IMPT inverse planning from the TPS should directly
optimize the dose and associated MUs. Some centers specify
treatment plans regarding the number of protons rather than
MUs.193 The resulting optimized plan is programmed directly
into the proton therapy system for delivery. Hence, the TPS
requires modeling the machine-dependent number of protons,
Mp, Gp, or MU factors, such as energy, and the dependency
on any beam-modifying device, such as the range shifter or
an aperture.
For commercial TPSs, if necessary, users can generally
incorporate dose-correction factors in the form of a dose-normalization table, typically a function of the beam energy or
additional parameters such as the modulation width for uniform fields. Zhu et al. published a detailed report on commissioning a commercial planning system for pencil-beam
scanning.178
11.F. Beam model veriﬁcation
The beam modeling and TPS model verification is an iterative process. Through sequences of modeling, verification,
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and remodeling, if needed, the dose model and measurement
should be brought to within an agreement of 2 mm/2% 98%
for uniform fields in homogeneous media. Usually, one
begins with the chosen reference field. The verification continues by investigating simple uniform fields of varying cubic
dimensions at different depths, with and without beam-modifying devices. As examples, Table V presents some possible
rectilinear field for dose model verification and, Fig. 4 shows
a comparison of a few rectilinear field TPS dose calculations
compared with ionization chamber measurements.
If repainting is employed, the simple uniform fields should
be evaluated with it as well. The beam model should also be
verified for any beam-modifying devices used. In the case of
EAs, the spot size and penumbra width should be measured
as a function of the air gap and beam configuration with the
EA, and the TPS should accurately model the observed trend.
IMPT systems degrading energy in the nozzle are a particular
case of a binary EA system.194 The verification of the beam
model across the range of absorber function is recommended.
The final verification proceeds with preclinical, patient-specific QA field deliveries.178 It is recommended that the passing
criteria for inhomogeneous fields be 3%/3 mm, with 95% of
the points passing.

TABLE V. Possible rectilinear fields for TPS dose model verification.
WET range
[cm]

Modulation
[cm]

Square fields
[cm2]

Oblong fields
[cm2]
2 × 30, 4 × 30

4

1, 2, 4

2, 5, 10, 20, max

6

3, 5

2, 5, 10, 20, max

2 × 30, 4 × 30

8

4, 6, 8

2, 5, 10, 20, max

2 × 30, 4 × 30

10

4, 6, 8

2, 5, 10, 20, max

12

6, 8, 10

2, 5, 10, 20, max

16
20

6, 8, 10
6, 8, 10, 12

2, 5, 10, 20, max
2, 5, 10, 20, max

24

6, 8, 12

2, 5, 10, 20, max

28

6, 8, 10, 14

2, 5, 10, 20, max

32

6, 8, 10, 15

2, 5, 10, 20, max

4×8
6×3

FIG. 4. Rectilinear verification fields from a synchrotron-based scanning system (a) longitudinal and (b) lateral comparing modeled dose distribution with ionization chamber measurements. The longitudinal comparisons are indicated by their SOBP widths, and the lateral comparisons are labeled according to their Range,
Modulation width (SOBP), square Field size, and measurement Depth in x centimeters according to RxMxFxDx.
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11.G. Role of Monte Carlo in data modeling
There are two situations in which MC simulations may be
preferable to direct measurements: the first is when the total
amount of data necessary to commission the system is such
that opening the facility could be delayed because of the time
needed to acquire the data, and the second is when limitations
in the measurement make it difficult to obtain the necessary
commissioning data. In either circumstance, the MC codes
used need to be well understood and validated with measurements. The MC model is based on the physical devices and
locations of the beamline components, most notably the nozzle, an example of which is presented in Fig. 5.
Most TPSs require integral depth-dose curves as input.
Measuring these curves with a large-diameter ionization
chamber and motorized water tank can be very time-consuming. Also, for large spot sizes, the commercially available ionization chambers may be too small to capture all the primary
protons and secondary particles at all depths in the water
tank. Figure 2 illustrates this point.
Because the design data are known well in advance of
clinical operations, MC commissioning data can also be
acquired well in advance. There are no practical limits on the
detector size used in MC simulations in determining the
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integral dose. However, MC data are typically in units that
are not easily converted to useful units for beam commissioning. Therefore, it is necessary to normalize the integral depthdose curve with a single measurement obtained using a Bragg
peak chamber at a suitable depth.209 Because of the ionization chamber’s finite size, this normalization may need to be
corrected by modeling the ratio of the measured integral
doses for the finite-size chamber and a large chamber209 or
by carefully measuring the beam profile at the normalization
point.195
Similarly, planning systems require multiple spot profiles
along both the major and minor axes of the beam spot, which
can be elliptical.209 Depending on the TPS, these profiles
may be in water or air. The low-dose part of the spot dose
profiles is most easily resolved by using MC simulations.210
12. END-TO-END VERIFICATION
Due to the complexity of IMPT systems and their internal
interactions and dependencies, it is recommended that endto-end verification must be performed before the onset of
patient treatments. It is also recommended that the end-toend verification should be performed for the typical clinical
treatment sites representing the intended practice.

FIG. 5. Schematic layout (bottom) of a scanning nozzle showing physical dimensions used for modeling and the scale model representation used for calculation
(top).4 [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE VI. Test cases.
Case type

Conditions

Field orientations

Test intent

Brain tumor
Upper abdomen/small
lung tumor

3 fields, 2 Gy per fraction
2 fields, 2 Gy per fraction, ~0.5liter PTV

1 lateral, 2 non-coplanar
1 lateral, 1 anterior

High-accuracy positioning
Target motion/gating

Sarcoma

2 fields, 2 Gy per fraction, ~2.5liter PTV

1 lateral, 1 oblique

Large-field penumbra, delivery time dose uniformity,
shallow dose, surface dose

Large lung tumor

3 fields, 2 Gy per fraction, ~1.5liter PTV

1 anterior, 1 posterior, 1 oblique

Large-target dose uniformity, Under-couch beam
clearance

Localized prostate
cancer

2 fields, 3 Gy per fraction, ~0.5liter PTV

2 lateral or lateral oblique fields

Deep-seated target, penumbra at depth

Craniospinal tumor

3–4 fields, 2 Gy per fraction, ~1 to
1.5-liter PTV

2 coplanar +2 posterior fields, all
fields matched

Multifield setup, image guidance, field matching at depth

12.A. Scope of end-to-end veriﬁcation
The initial end-to-end testing should include the following: a simple phantom with slabs of water-equivalent plastic,
low- and high-Z materials with known range-loss properties,
and a simple target accommodating an ionization chamber.
The water equivalent slabs should be evaluated for their
expected range loss using a water phantom prior to use.66
Commercially available options are available.211 Subsequently, more advanced phantoms and dosimetry techniques
can be used. End-to-end testing serves the following needs:
TPS/TMS/TDS interface testing, PPS testing, dose distribution alignment with the IG system, patient-specific device
fabrication, associated quality assurance, and staff training.
Table VI lists a set of possible test cases designed to test
planning and delivery system limits.
12.B. End-to-end testing methods and materials
Phantoms can be acquired to test these cases,212,213 or clinical treatment fields may be planned based on a patient’s CT
data set and recomputed in a homogeneous water phantom
before the clinical treatment fields are delivered to the phantom and measured. Anthropomorphic phantoms are to be preferred because they mimic human treatment better and
provide a more realistic training component for the staff.
They may also be more representative of geometric conditions, such as air gaps. The phantom-based method should be
used whenever the facility adds new types of significantly different anatomical clinical targets.
After the beamlines (or delivery system), TPS, CT simulator, TMS, and patient imaging and alignment system have all
been verified, the next step is to test the simulation, treatment
planning, and delivery process’s integrated functionality by
performing end-to-end testing with a suitable phantom.
There should be space in the phantom to insert suitable
dosimeters, such as TLDs, ion chambers, or film. Again,
some dosimeters have a LET dependence, and the physicist
should be aware of these. It is also necessary to have accurate
knowledge of the proton-relative RLSP of the phantom’s various materials in the irradiation field. The IROC has several
Medical Physics, 48 (1), January 2021

mailable phantoms suitable for dose verification for targets in
the prostate, lung, liver, brain, and spine. Commercially available phantoms can also be used for end-to-end testing. A
dynamic or moving phantom should also be used to test the
accuracy of the motion-management techniques used to treat
moving targets.
After acquiring the CT images of the phantom and transferring them to the TPS, the validity of the CTN to RLSP
conversion should be checked before treatment planning. The
WETs of selected regions containing different materials can
be obtained in the TPS and should be compared with the
measured values. A suitable treatment plan should then be
created in the TPS and put through the institutional QA
checks before it is transferred to the TMS. Depending on the
system, planar or volumetric imaging data should be prepared
for IG. If used in the plan, apertures and range compensators
are fabricated and should also undergo a QA process.
The treatment plan should be delivered to the phantom-appropriate dosimeters after the pretreatment QA process has
been satisfied. The phantom should be set up by using the IG
system. The necessary couch shifts should be determined by
the IG software and applied to position the target in the treatment position. If used, patient- and device-identification barcode readers should be included during this end-to-end test.
The treatment delivery in clinical treatment mode should
proceed and be recorded in the TMS. The treatment control
system log should be checked to ensure that the field beam
parameters delivered agree with those planned. The measured
point dose and 2D dose-distribution values should be compared with those from the treatment plan. They should meet a
minimum criterion of 3%/3mm, with 95% of the points passing.
12.C. End-to-end testing details
Unique to modulated beam delivery is a large amount of
data used to specify the energy, position, and MUs for each
spot. The application of a control point has a variety of vendor interpretations. A control point describes which parameters of the treatment machine change during beam delivery.
In IMPT, control points have been used to describe energy

Range
calculation

Geometric
positioning

Dose and range
calculations

Dose and range
calculations

Range

Dose

SOBP
measurement
error

Image guidance

In-patient
tissue
heterogeneities

Radiotherapy
planning
system

Clinical
commissioning
data acquisition

Clinical
commissioning
data acquisition

Clinical
commissioning
data acquisition

Error type

CT calibration
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Commissioning
error

Dose calibration
error

Range
measurement
error

Dose modeling

CTN limited
range and dose
calculation
algorithm

Commissioning
error

CTN to RLSP
agreement

Error source

2

2

2

3

3

10

10

Occurrence
(O)

SOBP measurement
errors occur seldom

Dose calibration error is
unlikely, but could occur

Range measurement
errors occur seldom

Volumetric dose
distribution calculation
errors sometimes occur

Patient inhomogeneities
factor into a limited
number of cases and
current dose algorithms
handle most of them
fairly well

Geometric positioning
errors commonly occur
during commissioning

CT calibration
mismatches may occur
more than 5% of the time

(O) justification

TABLE VII. Potential errors in the commissioning process and their mitigations.

10

Over or under
modulation could
produce a toxicity
(over) or high dose
in the target
(under)

Over or underdose
entire target

(S) impact

Severity
(S)

10

Over or undershoot
could produce a
toxicity (over) or
not provide local
control (under)

The magnitude of
the severity from
modest (<5%)
volumetric dose
errors is low.

Local over and
under dose near
heterogeneity and
increased range
uncertainty.

Mispositioning of
patient relative to
beam could over or
under dose

Beam over or
undershoot could
produce a toxicity
(over) or not
provide local
control (under)

(S) impact

10

2

10

10

10

Severity
(S)

Error is readily
detectable if
comparison is
made

1

8

8

Difficult to detect
without
independent
comparison

Difficult to detect
without
independent
comparison

(D) justification

Because the error
magnitude is low, it
is difficult to detect

6

lack of
detectability (D)

The possible errors
are readily
detectable and
materials of high
density are readily
identifiable

Geometric errors
are easily
identified.

The error should be
found during range
verifications using
scanned phantoms

(D) justification

1

1

2

lack of
detectability
(D)

160

160

risk
priority
number
RPN = O
*S*D

20

36

30

100

200

risk
priority
number
RPN = O
*S*D

Verify a subset of commissioned
SOBPs with IROC credentialing
service

Calibration according to
established protocols. Verify
calibrated dose using IROC
service

Error Mitigation

Achieve agreement between
physical measurements in water,
Monte Carlo modeling (if used),
and published range tables to
within 1 mm

Perform extensive patient
specific field verifications at
many energies, depths and field
sizes. Find the limitations of the
dose calculation model

See Section 6.C on high atomic
number materials. Refer also to
TG-202: Physical Uncertainties
in the Planning and Delivery of
Light Ion Beam Treatments

Verify radiation field and image
guidance system orientation and
alignment independently with
the IROC credentialing service

The CTN to RLSP curve should
be reviewed by IROC

Error mitigation
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Perform end-to-end tests in
“treatment mode” and
quantitatively verify asymmetric
field alignment and dose in
phantom
640
8
10
Process errors are often
identified in end-to-end
testing

Could result in
patient
mistreatment

Difficult to detect
without testing
system as a whole

Fully characterize spot tails and
dose halo with at least 2
methods, or 1 method + Monte
Carlo
240
8
5
Spot profile
measurement errors can
occur with medium
frequency

The dose model is
not highly sensitive
to modest spot
profile
measurement
errors

Difficult to detect
without
independent
comparison

48
2
8

8
System
integration
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Systemic

6
Commissioning/
modeling error
Spot
characterization
measurement
error

layers or transition points within energy layers. Some TPS
and proton therapy control systems may have specific requirements, such as zero-weighted spots, to terminate a control
point or end of treatment field delivery.
Intensity modulated proton therapy–specific areas of interest for commissioning regarding the TMS are the maximum
deliverable versus recordable MU and the minimum MU.
Clinically, before patient treatment commences, it is good
practice to test patient-specific fields in the QA mode of the
TMS, with the TDS in the treatment mode. After the treatment is delivered, the number of MU, spots, and spot positions that were delivered are uploaded from the TDS to the
TMS for record-keeping and verification.209
An essential feature of the TMS or TDS (system-specific)
is its ability to recover and deliver the remaining treatment in
the event of a failure of either the TDS or the TMS, as the
entire spot pattern must be delivered to treat the target with
the prescribed dose. This recovery ability should be tested,
especially when there is a discrepancy between the TDS and
TMS. One possible approach is to deliberately cause failures
in both the delivery system and the TMS. After such a failure,
the number of spots delivered should be verified. The number
of remaining spots should be determined and then delivered.
A three-film test procedure was described by Gillin et al.209
13. POSSIBLE COMMISSIONING ERRORS AND
MITIGATIONS
During commissioning, any measurement deviation from
expected values should be investigated. The data should be
consistent with each other. It is recommended that commissioning data and results be compared to published values
where these are available. It is further recommended that the
IROC credential the commissioned system. These steps can
help avoid a major error. Table VII lists possible proton therapy commissioning errors that should be addressed as part of
the commissioning process.
14. SUMMARY OF RECOMMENDATIONS
Below in Table VIII are the significant recommendations
of TG-185. The commissioning team should produce a clinical commissioning report covering all the technical topics
presented here. The commissioning data and results should
be archived in a secure location for later reference. Portions
of the data serve as a baseline for machine-specific quality
assurance, as outlined in the TG-224.2
a)
Author to whom correspondence should be addressed. Electronic mail:
jonathan.brent.farr@cern.ch.
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3

IDD measurement errors
occur seldom

Wrong profile or
magnitude could
produce an
incorrect planning
model

Readily detectable
from dose model
validation
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Error type

Occurrence
(O)
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Severity
(S)

(S) impact
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detectability
(D)

(D) justification

risk
priority
number
RPN = O
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TABLE VII. Continued.

Verify a subset of commissioned
integral depth doses with IROC
credentialing service. Correct
with Monte Carlo as necessary
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TABLE VIII. Major recommendations for proton therapy clinical commissioning.
Section no.

Title

Recommendation

4
4

Education, training, and timing
Education, training, and timing

It is recommended that the commissioning team members (team) receive training in proton therapy
The team should receive didactic education on general proton therapy principles and practice

4

Education, training, and timing

It is recommended that the new proton beam user setup the TPS as early as possible for planning exercises

4

Education, training, and timing

The team should be trained by the vendor regarding the specific operation of their proton therapy equipment

4

Education, training, and timing

The team should be trained by the vendor on the dosimetry equipment and systems

4

Education, training, and timing

4

Education, training, and timing

Before commissioning a proton therapy system, it is recommended that the user be fully aware of the
limitations of sensor and detector use in proton therapy
External review by experienced planners is recommended before a system is first used to treat a patient. The
external analysis should be performed by a multidisciplinary team, including at least one radiation oncologist
and one medical physicist with extensive experience in proton therapy planning. The reviewers should review
and suggest improvements for the proposed proton treatment planning policies and procedures as well as a
representative sample of treatment plans covering the intended sites for treatment

5

Commissioning a CT scanner for
proton therapy planning

It is recommended that a CT scanner be commissioned as a radiotherapy simulation scanner (CT simulator)

5

Commissioning a CT scanner for
proton therapy planning
Commissioning a CT scanner for
proton therapy planning

It is recommended that X-ray CT number (CTN) to relative linear stopping power (RLSP) conversion
functions should be determined in order to provide accurate proton plan optimization and dose calculations
A standard phantom should be used, and verification of the CTN-RLSP fit from the Imaging and Radiation
Oncology Core (IROC) Houston Quality Assurance Center is recommended

5

Commissioning a CT scanner for
proton therapy planning

It is recommended that the resulting conversion functions should be accurate to within 2% for soft tissues
with near unit density

5

Commissioning a CT scanner for
proton therapy planning

It is recommended that a separate conversion function should be generated for each set of CT scanner
parameters (protocols) with different kVp, scan field-of-view size, and reconstruction kernel

5

Commissioning a CT scanner for
proton therapy planning

It is recommended that if a plastic phantom must be used to generate the conversion function, offsets should
be applied to construct a real tissue function

6

Ancillary devices and materials

It is recommended that any time a foreign material is introduced into the proton beam, its beam path length
change be accounted for

6

Ancillary devices and materials

It is recommended that the alignment, uniformity, and WET be determined for each tabletop that will be used
for therapy

6

Ancillary devices and materials

A set of physical and radiologic tests should be carried out to ensure the uniformity of the treatment couches
to be used

6

Ancillary devices and materials

Because the WET function is nonlinear and begins to vary greatly at high angles, such high angles of
incidence are best avoided. Also, to be avoided are the couch edges

6

Ancillary devices and materials

It is recommended to override the density of high–atomic number materials by using a measured RLSP
corresponding to the CTN from the CT-simulator calibration.

6

Ancillary devices and materials

When treating through high-density materials, single-field treatment plans should be avoided

6

Ancillary devices and materials

Monte Carlo dose modeling is suggested when treating through high-density materials. Based on the results
of modeling, suitable margins and a suitable number of fields should be used to provide sufficient robustness
against range uncertainty and dose shadow effects

7

Commissioning image guidance
systems for proton therapy

It is recommended that the accuracy of the PPS and IG system, including the accuracy of isocentric motion,
be verified by acceptance testing before clinical commissioning

7

Commissioning image guidance
systems for proton therapy

A setup accuracy guideline range is recommended that is synchronized with the treatment plan margins and
robustness

7

Commissioning image guidance
systems for proton therapy

It is recommended that the correct display of coordinate-based image data be verified as part of the IG
commissioning

7

Commissioning image guidance
systems for proton therapy

It is recommended that all clinical geometries intended for use have their IG process and correctness verified.
Examples include verifications of different patient orientations, such as prone/supine and feet-first or headfirst

7

Commissioning image guidance
systems for proton therapy

The dose associated with clinical imaging techniques should be determined

8

Treatment management system
commissioning

During commissioning, the TMS functionality should be validated concerning its correct data transfer and
recording

8

Treatment management system
commissioning

The recording and subsequent recovery of partially delivered fields should be verified using the TMS

8

Treatment management system
commissioning

It is recommended that the entire TMS-related workflow of patient verification, barcode scans (if used),
patient setup, treatment delivery, and dose/MU/beam geometry/overrides and partial delivery be verified

9

Proton machine absolute dose
calibration

Reference dose calibration should be performed according to the Nw-based method of calibrated ionization
dosimetry of TRS-398

5
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TABLE VIII. Continued.
Section no.

Title

Recommendation

9

Proton machine absolute dose
calibration

The calibration for IMPT systems can be performed in either a pristine beam or a SOBP, but SOBP calibration
is predominant

9

Proton machine absolute dose
calibration

Care should be taken with regard to recombination factors that depend on the ionization chamber size, bias,
and dose rate

9

Proton machine absolute dose
calibration

It is recommended not to exceed 1% correction for ionic recombination

9

Proton machine absolute dose
calibration
Proton machine absolute dose
calibration

It is the recommendation to use a calibrated, guarded, parallel-plate chamber for the PTS absolute absorbed
dose calibration
When the calibration is performed in a monoenergetic pristine beam, depths of at least 1 cm in water are
recommended

9

Proton machine absolute dose
calibration

When the calibration is performed using scanned monolayers, it is recommended to use a spot spacing that
reduced the field ripple to <1% in the vicinity of the measurement location

9

Proton machine absolute dose
calibration

It is recommended that the user conduct in-house uncertainty analyses for the absolute dose calibration

9

Proton machine absolute dose
calibration

The machine dose calibration for the reference field should be confirmed through the IROC before the first
patient treatment

10

Out-of-field Dose

It is recommended that the clinical staff be aware of the out-of-field dose magnitudes and distribution for their
system

11

Radiotherapy planning system
commissioning

Static, monoenergetic beamlets should be delivered for the IDD measurements. The IDD measurements
should be performed with a large-diameter parallel-plate ionization chamber. The parallel-plate ionization
chamber build-up values should be verified by the user. MLICs are not recommended for IDD acquisition

11

Radiotherapy planning system
commissioning
Radiotherapy planning system
commissioning

The large-diameter ionization chamber should be calibrated or cross-calibrated to a calibrated chamber
(Accredited Dosimetry Calibration Laboratory calibration) in a wide, flat, photon or proton field
The IDDs should be scaled for each energy as a function of the monitor units or the number of particles,
according to the requirements of the TPS

11

Radiotherapy planning system
commissioning

It is recommended that the scaling measurements be performed at shallow depth in a water phantom. Water
measurement depths of 1 to 2 cm are suggested

11

Radiotherapy planning system
commissioning

A scanning water phantom with sub- millimetric positioning accuracy should be used

11

Radiotherapy planning system
commissioning

Geometrically, all IDD scans should be performed at a fixed source-to-surface distance

11

Radiotherapy planning system
commissioning
Radiotherapy planning system
commissioning

The IDD curves should be corrected for beam losses on the detector and scaled to dose or # protons per
monitor chamber area
It is recommended that the lateral fluence distribution of the central-axis beam spot in air be measured in the
isocenter plane and at several distances proximal and distal to the isocenter plane along the beam axis (e.g., at
10 and 20 cm)

Radiotherapy planning system
commissioning
Radiotherapy planning system
commissioning

Consideration should be given to the lateral fluence halo with measurement and modeling

11

Radiotherapy planning system
commissioning

It is recommended that the dose model be validated using a mix of rectilinear and patient fields

11

Radiotherapy planning system
commissioning

Through sequences of modeling, verification, and remodeling, if needed, the dose model and measurement
should be brought to within agreement of 2 mm/2% 98% for uniform fields in homogeneous media

11

Radiotherapy planning system
commissioning

IMPT systems degrading energy in the nozzle are a special case of a binary EA system. Verification of the
beam model across the range of absorber function is recommended

11

Radiotherapy planning system
commissioning

It is recommended that the passing criteria for inhomogeneous fields be 3%/3 mm, with 95% of the points
passing

12

End-to-end verification

It is recommended that end-to-end verification must be performed prior to the onset of patient treatments

12

End-to-end verification

The measured point dose and 2D dose-distribution values should be compared with those from the treatment
plan and should meet a minimum criterion of 3%/3mm, with 95% of the points passing.

14

Possible commissioning errors
and mitigations

It is recommended that commissioning data and results be compared to published values where these are
available

14

Possible commissioning errors
and mitigations

It is recommended that the commissioned system be credentialed by the IROC

9

11

11

11
11
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The VSAD(s) of the magnet centers should be verified using individual scanned, monoenergetic pristine fields
(monolayers) delivered at low, medium, and high system energies, using in-air back-projection film exposures
at several positions along and perpendicular to the central beam axis of 50–50% radiation field widths
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147. Gomà C, Hofstetter-Boillat B, Safai S, Vörös S. Experimental validation of beam quality correction factors for proton beams. Phys Med
Biol. 2015;60:3207–3216.
148. Medin J. Implementation of water calorimetry in a 180 MeV scanned
pulsed proton beam including an experimental determination of kQ for
a Farmer chamber. Phys Med Biol. 2010;55:3287–3298.
149. Lin L, Kang M, Solberg TD, et al. Use of a novel two-dimensional ionization chamber array for pencil beam scanning proton therapy beam
quality assurance. J Appl Clin Med Phys. 2015;16:5323.
150. Seco J, Clasie B, Partridge M. Review on the characteristics of radiation detectors for dosimetry and imaging. Phys Med Biol. 2014;59:
R303–R347.
151. Moyers MF, Vatnitsky SM. Radiation therapy with light ions. In: van
Dyk J, ed. The Modern Technology of Radiation Oncology: A Compendium for Medical Physicists and Radiation Oncologists, 3rd edn.
Madison, Wisconsin: Medical Physics Publishing; 2013:183–222.
152. Boag JW, Currant J. Current collection and ionic recombination in
small cylindrical ionization chambers exposed to pulsed radiation. Br J
Radiol. 1980;53:471–478.
153. Rossomme S, Delor A, Lorentini S, et al. Three-voltage linear method
to determine ion recombination in proton and light-ion beams. Phys
Med Biol. 2020;65:045015.
154. Liszka M, Stolarczyk L, Klodowska M, et al. Ion recombination and
polarity correction factors for a plane-parallel ionization chamber in a
proton scanning beam. Med Phys. 2018;45:391–401.
155. Mirandola A, Magro G, Maestri D, et al. Determination of ion recombination and polarity effect correction factors for a plane-parallel ionization Bragg peak chamber under proton and carbon ion pencil beams.
Phys Med Biol. 2019;64:095010.
156. Vatnitsky S, Moyers M, Miller D, et al. Proton dosimetry inter-comparison based on the ICRU report 59 protocol. Radiother Oncol.
1999;51:273–279.
157. Farr JB, Mascia AE, Hsi WC, et al. Clinical characterization of a proton
beam continuous uniform scanning system with dose layer stacking.
Med Phys. 2008;35:4945–4954.
158. Nichiporov D, Kostjuchenko V, Puhl JM, et al. Investigation of applicability of alanine and radiochromic detectors to dosimetry of proton clinical beams. Appl Radiat Isot. 1995;46:1355–1362.
159. Summers P, Ibbott GS, Moyers MF, Grant RL, Followill DS. Comparison of clinical parameters for proton therapy in the United States. Int J
Radiat Oncol Biol Phys. 2012;84:S30.
160. Newhauser WD, Durante M. Assessing the risk of second malignancies
after modern radiotherapy. Nat Rev Cancer. 2011;11:438–448.
161. Ardenfors O, Dasu A, Lillhok J, Persson L, Gudowska I. Out-of-field
doses from secondary radiation produced in proton therapy and the
associated risk of radiation-induced cancer from a brain tumor treatment. Phys Med. 2018;53:129–136.
162. Brodin NP, Munck Af Rosenschold P, Aznar MC, et al. Radiobiological
risk estimates of adverse events and secondary cancer for proton and
photon radiation therapy of pediatric medulloblastoma. Acta Oncol.
2011;50:806–816.
163. Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant
neoplasms from proton therapy and intensity-modulated x-ray therapy
for early-stage prostate cancer. Int J Radiat Oncol Biol Phys.
2009;74:616–622.
164. Fuji H, Schneider U, Ishida Y, et al. Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam
therapy and intensity modulated radiation therapy in treatment of neuroblastomas. Radiat Oncol. 2013;8:255.
165. Paganetti H, Depauw N, Johnson A, Forman RB, Lau J, Jimenez R.
The risk for developing a secondary cancer after breast radiation therapy: comparison of photon and proton techniques. Radiother Oncol.
2020;149:212–218.
166. Tamura M, Sakurai H, Mizumoto M, et al. Lifetime attributable risk of
radiation-induced secondary cancer from proton beam therapy

Medical Physics, 48 (1), January 2021

e29

167.

168.

169.
170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

180.
181.

182.
183.

184.

185.

186.

187.

188.
189.

compared with that of intensity-modulated X-ray therapy in randomly
sampled pediatric cancer patients. J Radiat Res. 2017;58:363–371.
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